No biomarker	Triple Negative Breast Cancer	No biomarker	Triple Negative Breast Cancer	pembrolizumab Sensitive: A1 - Approval Merck (MSD) Press Release - Today (New A1) pembrolizumab Sensitive : A1 Merck (MSD) Press Release -	pembrolizumab Sensitive: A1 - Approval Merck (MSD) Press Release - Today pembrolizumab Sensitive : A1 Merck (MSD) Press Release - Today - (New A1)
No biomarker	Triple Negative Breast Cancer	No biomarker	Triple Negative Breast Cancer	XMT-1660 Sensitive: B - Late Trials Mersana Therapeutics Press Release - 2 weeks (New B) XMT-1660 Sensitive : B Mersana Therapeutics Press Release - 2wk	XMT-1660 Sensitive: B - Late Trials Mersana Therapeutics Press Release - 2 weeks XMT-1660 Sensitive : B Mersana Therapeutics Press Release - 2 weeks - (New B)
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	Immunotherapy Sensitive: A2 - Guideline ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : A2 ESMO 2022 - 3wk	Immunotherapy Sensitive: A2 - Guideline ESMO 2022 - 3 weeks Immunotherapy Sensitive : A2 ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : C1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : C1
No biomarker	Triple Negative Breast Cancer	No biomarker	Triple Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1
No biomarker	Triple Negative Breast Cancer	No biomarker	Triple Negative Breast Cancer	CaT Sensitive: A2 - Guideline CaT Sensitive : A2	CaT Sensitive: A2 - Guideline CaT Sensitive : A2
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	vinorelbine tartrate Sensitive: A2 - Guideline vinorelbine tartrate Sensitive : A2	vinorelbine tartrate Sensitive: A2 - Guideline vinorelbine tartrate Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	vinorelbine tartrate Sensitive: A2 - Guideline vinorelbine tartrate Sensitive : A2	vinorelbine tartrate Sensitive: A2 - Guideline vinorelbine tartrate Sensitive : A2
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2
No biomarker	Triple Negative Breast Cancer	No biomarker	Triple Negative Breast Cancer	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	PARP inhibitor Sensitive: A2 - Guideline PARP inhibitor Sensitive : A2	PARP inhibitor Sensitive: A2 - Guideline PARP inhibitor Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	PARP inhibitor Sensitive: A2 - Guideline PARP inhibitor Sensitive : A2	PARP inhibitor Sensitive: A2 - Guideline PARP inhibitor Sensitive : A2
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	doxorubicin hydrochloride Sensitive: A2 - Guideline doxorubicin hydrochloride Sensitive : A2	doxorubicin hydrochloride Sensitive: A2 - Guideline doxorubicin hydrochloride Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	doxorubicin hydrochloride Sensitive: A2 - Guideline doxorubicin hydrochloride Sensitive : A2	doxorubicin hydrochloride Sensitive: A2 - Guideline doxorubicin hydrochloride Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	CaT Sensitive: B - Late Trials CaT Sensitive : B	CaT Sensitive: B - Late Trials CaT Sensitive : B
No biomarker	Triple Negative Breast Cancer	No biomarker	Triple Negative Breast Cancer	IPI-549 Sensitive: B - Late Trials IPI-549 Sensitive : B	IPI-549 Sensitive: B - Late Trials IPI-549 Sensitive : B
AKT1 mutation	Triple Negative Breast Cancer	AKT1 mutation	Triple Negative Breast Cancer	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B

Triple Negative Breast Cancer

Associations(281)

Associations
(281)